Reply to Crimi, C.; Cortegiani, A. Comment on “Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419”
1
Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 22000, Taiwan
2
Graduate Institute of Medicine, Yuan-Ze University, Taoyuan City 32003, Taiwan
*
Author to whom correspondence should be addressed.
Life 2022, 12(10), 1626; https://doi.org/10.3390/life12101626
Submission received: 11 October 2022
/
Accepted: 14 October 2022
/
Published: 18 October 2022
(This article belongs to the Section Medical Research)
Thanks for Crimi et al.’s comment [1]. The following is our response to your comment.
We recommend HFNC as a first-line treatment for patients with “severe” COVID-19 in the small discussion chapter of this review article. We are sorry for not giving clear definition of severe COVID-19 in our discussion chapter. The definition of severe COVID-19 here is to use 6–15 L O2/min (FiO2 0.4–0.6) to achieve the target SpO2 (≥90% for nonpregnant patients and ≥92–95% for pregnant patients) [2]. In other words, HFNC may be suggested as a first-line treatment in patients with severe COVID-19 if COT (conventional oxygen therapy) can not meet adequate oxygenation in those patients, and IMV (invasive mechanical ventilation) is not indicated at the time. However, more well-designed RCTs in the future are needed to support this idea.
Indeed, a personalized and stepwise approach is important in treating COVID-19 patients with hypoxemic respiratory failure. Although there is still uncertainty about optimal oxygen strategy in COVID-19 patients with hypoxemic respiratory failure, HFNC may play an important role in a stepwise approach because of its great comfort for the patients.
We have learned much from your comment. Thank you again.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Crimi, C.; Cortegiani, A. Comment on Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419. Life 2022, 12, 1625. [Google Scholar] [CrossRef]
- Bonnesen, B.; Jensen, J.-U.S.; Jeschke, K.N.; Mathioudakis, A.G.; Corlateanu, A.; Hansen, E.F.; Weinreich, U.M.; Hilberg, O.; Sivapalan, P. Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation. Diagnostics 2021, 11, 2259. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Liu, C.-W.; Cheng, S.-L. Reply to Crimi, C.; Cortegiani, A. Comment on “Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419”. Life 2022, 12, 1626. https://doi.org/10.3390/life12101626
AMA Style
Liu C-W, Cheng S-L. Reply to Crimi, C.; Cortegiani, A. Comment on “Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419”. Life. 2022; 12(10):1626. https://doi.org/10.3390/life12101626
Chicago/Turabian StyleLiu, Cheng-Wei, and Shih-Lung Cheng. 2022. "Reply to Crimi, C.; Cortegiani, A. Comment on “Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419”" Life 12, no. 10: 1626. https://doi.org/10.3390/life12101626
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
